(ALUR) Allurion Technologies - Ratings and Ratios

Allurion Technologies, Inc. (NYSE:ALUR) is a medical technology company pioneering innovative solutions to combat obesity. Its flagship product, the Allurion Program, integrates a swallowable, procedure-less intragastric balloon with AI-driven remote patient monitoring, behavior modification tools, and telehealth services. The Allurion Balloon is designed for ease of use, requiring no endoscopy or surgery, and is paired with the Allurion Virtual Care Suite, which includes AI-powered tracking, personalized coaching, and secure communication platforms. Headquartered in Natick, Massachusetts, Allurion aims to redefine weight loss treatment with a comprehensive, tech-enabled approach.

Category: Ticker Symbol: ALUR Exchange: NYSE Type: Common Stock Country Origin: United States GICS Sub Industry: Specialized Consumer Services

Technical Data (as of latest update): Average Volume 20d: 182,100 shares Last Price: $2.43 SMA 20: $3.92 SMA 50: $5.52 SMA 200: $16.98 ATR: $1.18

Fundamental Data: Market Cap: $18.96M USD P/E Ratio: 0.00 Forward P/E: 0.00 P/B Ratio: 0.00 P/S Ratio: 0.55 Return on Equity (RoE): 38.80%

3-Month Forecast: Based on the technical and fundamental data, ALUR is expected to face headwinds in the near term. The stock is trading below its SMA 20, SMA 50, and SMA 200, indicating a bearish trend. The ATR of $1.18 suggests heightened volatility, with potential price swings impacting short-term stability. - Resistance Levels: $3.50 - $5.00 - Support Levels: $2.00 - $1.80 Fundamentally, the companys high RoE of 38.80% signals strong profitability, but the lack of positive P/E and P/B ratios raises concerns about valuation. The low P/S ratio of 0.55 may attract value investors, but the stocks speculative nature and limited market cap warrant caution. Over the next three months, ALUR is likely to remain under pressure, with potential sideways movement or further decline unless driven by positive catalysts.